Authors
Latest:
Developing Controllable Tumor Infiltrating Lymphocyte TherapiesJan ter Meulen, MD, PhD, chief scientific officer, Obsidian Therapeutics, discussed the potential of the cytoDRIVE platform.
Latest:
Breanna DiAndreth, PhD, on Improving Selective Targeting of Tumor CellsThe scientist at A2 Biotherapeutics discussed the company’s dual-receptor Tmod technology.
Latest:
Looking Forward in Relapsed/Refractory Multiple Myeloma TreatmentsJames Hoffman, MD, leads a discussion about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.
Latest:
Jennifer Kwon, PhD, on Reducing LDL Cholesterol in NHPs With Epigenome EditingThe senior scientist at Tune Therapeutics discussed preclinical research presented at the ASGCT 2023 meeting.
Latest:
Tackling Deceased Kidney Transplant and Severe Scleroderma With Cell TherapyScott Requadt, chief executive officer, Talaris Therapeutics, discussed the phase 2 FREEDOM-3 trial and preclinical studies of the cell therapy FCR-001.
Latest:
Gene Editing's Potential for COVID-19 and Other IndicationsNew human gene editing therapies, drug discoveries, targets, and CRISPR technology holds the potential to usher in a new age in medicine.
Latest:
Vishal Patel, MD, on the Potential Advantages of a Gene Therapy Approach for Polycystic Kidney DiseasePatel discussed the potential advantages of his team’s gene therapy approach compared to an investigational PKD drug.
Latest:
Working Toward a Single Dose Gene Therapy for Type 1 Gaucher DiseaseOlga Uspenskaya, MD, PhD, vice president, clinical development, Prevail Therapeutics, discussed the PROCEED trial of PR001.
Latest:
Colleen E. Annesley, MD, on Continued Research With T-APCs to Enhance Cell Therapy PersistenceThe medical Director and interim co-Chief Medical Officer at Seattle Children's Therapeutics discussed possible research to move forward with CD19 T-APCs for patients with B-ALL.
Latest:
Unique Challenges With Gene Therapy in Duchenne Muscular DystrophyThe co-founder, president, and chief executive officer of Solid Biosciences, whose own son has DMD, discussed challenges in developing gene therapies for DMD.
Latest:
Weijia Fang, MD, and Tianhang Luo, MD, on EpCAM-Targeted CAR-T Therapy in Advanced Colorectal and Gastric CancerFang recently presented at the European Society for Medical Oncology (ESMO) 2022 Congress.
Latest:
Carol Miao, PhD, on the Importance of Continuing Preclinical Research in Gene TherapyThe principal investigator at Seattle Children’s Research Institute discussed the continuing need to share preclinical research at conferences even as more gene therapies enter the clinic.
Latest:
Optimizing COVID-19 Vaccines in Patients Receiving CAR T Therapy: Muhammad Bilal Abid, MD, MRCPThe assistant professor of medicine at the Medical College of Wisconsin discussed immune-compromising factors that are indigenous to CAR T-cell therapy recipients.
Latest:
Swetha Kambhampati, MD, on the Potential of Bringing Brexu-cel to Earlier Treatment SettingsThe assistant professor in the Division of Lymphoma at City of Hope discussed the potential implications of real-world data she presented at ASCO’s 2023 conference.
Latest:
Gavin Macbeath, PhD, on Screening for Off-Target EffectsThe chief scientific officer at TScan Therapeutics discussed the company’s SafetyScan technology.
Latest:
Gene Therapy Optogenetics Combination Efficacious in Retinitis Pigmentosa: José-Alain Sahel, MDThe professor from University of Pittsburgh School of Medicine discussed the combination of an optogenetics device and gene therapy in treatment of RP.
Latest:
Developing Safer, Next-Generation CAR T-Cell TherapiesRick Fair, president and chief executive officer, Bellicum Pharmaceuticals, discussed the company’s programs and future plans.
Latest:
Stephan Züchner, MD, PhD, on the Future of Gene Therapy and Diagnostic ScreeningThe professor for human genetics and neurology at the University of Miami Miller School of Medicine discussed the rapidly changing landscape of diagnosing and treating genetic disorders.
Latest:
Raj Chovatiya, MD, PhD, on Investigating HSV-1 Vectors in Collagen-Based DisordersThe assistant professor dermatology at the Northwestern University Feinberg School of Medicine discussed the potential for further research enabled by B-VEC.
Latest:
Latest Updates on Geographic Atrophy Gene Therapy FOCUS Trial: Nadia K. Waheed, MDThe associate professor from Tufts University School of Medicine discussed the latest updates on the FOCUS trial.
Latest:
Mitigating Cytokine Release Syndrome in CAR T for Multiple Myeloma: Krina K. Patel, MD, MScThe associate professor from The University of Texas MD Anderson Cancer Center discussed mitigating CAR T-cell therapy–related cytokine release syndrome in multiple myeloma.
Latest:
Orca-T for Graft-Versus-Host Disease: Mehrdad Abedi, MDThe professor of medicine at the UC Davis Comprehensive Cancer Center discussed Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.
Latest:
Nick Boyle, PhD, on Advantages of In Vivo CAR TherapiesThe chief executive officer of Abintus Bio discussed the company’s in vivo approach and how it could help expand patient access to cell therapies.
Latest:
Adriana Rossi, MD and Luciano J. Costa, MD, PhD on Earlier CAR T in Multiple MyelomaOncologist discuss the possibility of earlier-line CAR T-cell therapies in MM.
Latest:
Acclaim-2 Begins Enrollment to Asses Ozeplasmid Plus Pembrolizumab in Late-Stage NSC Lung CancerThe phase 1/2 study (NCT05062980) has officially opened enrollment for patients with late-stage non-small cell lung cancer, with plans to initiate patient screening.
Latest:
More Data Supports Approval as Lifileucel Review for Melanoma Pushed BackThe new PDUFA date of lifileucel is set for Februrary 24, 2024.
Latest:
Amy Pooler, PhD, on Improving Gene Delivery to the CNSThe vice president of neuroscience at Sangamo Therapeutics discussed identifying novel capsids with improved neuronal transduction to the CNS.
Latest:
Mechanism of VB-111 in Treating Ovarian Cancer: Bradley Monk, MD, FACOG, FACSBradley Monk, MD, FACOG, FACS, discusses the mechanism of VB-111 in patients with ovarian cancer.
Latest:
Peter Marks, MD, PhD, on Bringing More Gene Therapies to PatientsThe director of the Center for Biologics Evaluation and Research at the FDA discussed his keynote speech at the 2023 MDA Conference.
Latest:
Cory R. Nicholas, PhD, on Future Plans for Additional Research With Epilepsy Cell Therapy NRTX-1001The cofounder and CEO of Neurona Therapeutics discussed the company’s goals to evaluate the cell therapy in more types of epilepsy and potentially even in Alzheimer disease.
